巨子 ICON - 財經股票資訊及專家分析
快訊
資訊
    虛擬市場
    搜尋 股票/指數/編號

    快訊

    資訊

    Assembly Biosciences

    ASMB
    1.660
    0.080
    4.60%
    最少15分鐘延遲,股票資訊由第三方資訊供應商提供
    ・Assembly Biosciences - 延遲價格・最後更新於 29/09 12:00
    最高位
    1.715
    最低位
    1.640
    開市價
    --
    前收市價
    1.740
    成交量(千)
    6.10
    成交額(百萬)
    0.07
    買入
    --
    賣出
    --
    每手股數
    --
    市值(百萬)
    80.41
    市盈率
    --
    息率
    --
    差價
    --
    52週高低
    3.510 - 1.320
    所有資料不保證絕對正確、完整、或實時,僅作為參考使用。投資涉及風險,過往業績並不代表將來表現,作任何投資決定或交易前,閣下應諮詢獨立專業意見。所有內容均不構成投資建議。

    企業資料

    公司名稱
    Assembly Biosciences
    證券代碼
    ASMB.US
    所屬板塊
    Biotechnology
    公司業務
    Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two innovative platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health to a dysbiotic microbiome. The company's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Assembly has discovered several novel core protein Allosteric Modulators, which are small molecules that directly target and allosterically modulate the HBV core protein. The majority of the revenue is generated from the HBV cure program.
    發行量
    47861677
    公司總部
    331 Oyster Point Boulevard, Fourth Floor
    公司網址
    https://www.assemblybio.com
    公司電郵
    info@assemblybio.com
    公司電話
    +1 833 509-4583
    暫無內容

    關於

    Assembly Biosciences(ASMB.US)所屬的行業板塊為Biotechnology。
    Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two innovative platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health to a dysbiotic microbiome. The company's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Assembly has discovered several novel core protein Allosteric Modulators, which are small molecules that directly target and allosterically modulate the HBV core protein. The majority of the revenue is generated from the HBV cure program.
    詳細公司背景可參考: https://www.assemblybio.com